CD33 and neoplasm: Indeed, in vitro tumor cell killing assays demonstrated that Allo15CAR33-NKT cells were markedly more effective at eliminating primary blast cells compared to CAR33-T cells, notably targeting CD33-negative LSPCs, which CAR33-T cells failed to engage (Fig. 5p).